Today: Mega-Fusion zwischen Astra Zeneca und Bristol-Myers?
Die Pharmakonzerne haben laut eines Berichts über eine Fusion gesprochen. Was spräche dafür – und was dagegen? Und: Die US-Notenbank stützt den Yen. Was das für Anleger bedeutet.
Astra Zeneca and Bristol-Myers may be discussing a potential mega-merger today, according to a report. This deal would be one of the largest in the world, according to Helena Smolak, a Pharmareport correspondent for Handelsblatt. Smolak explains on her podcast why such a merger could be a possibility for both companies, as well as what would be against a merger.
Laura de la Motte, a Handelsblatt reporter, discusses how the shares of the two pharma companies have been trading today in her market report. Analysts are skeptical about a possible mega-pharma merger. In the main part of the show, the focus is on the Japanese Yen. For the first time in nearly 30 years, the US Federal Reserve and the Bank of Japan have jointly strengthened the Yen through a currency intervention.
This has implications for Japan's interest policy and for investors. Stefan Reccius, a Handelsblatt expert on the Bank of Japan, explains in this episode how the strengthening of the Yen affects Japanese stocks and government bonds.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
